Pharma THC Cannabinoid Research

Pharma THC Research Dashboard

130

Primary Studies

56

Related Studies

186

Total Studies

Clinical Studies

15

Clinical Meta-analyses

36

Double-blind human trials

17

Clinical human trials

Pre-Clinical Studies

45

Meta-analyses/Reviews

8

Animal studies

2

Laboratory studies

What am I missing as a non-subscriber?

To see a full dashboard with study details and filtering, go to our DEMO page.

As a subscriber, you will be able to access dashboard insights including chemotype overviews and dosing summaries for medical conditions and organ system and receptor breakdowns for cannabinoid and terpene searches. Study lists present important guidance including dosing and chemotype information with the ability to drill down to the published material. And all outputs are fully filterable, to help find just the information you need. Stay up-to-date with the science of cannabis and the endocannabinoid system with CannaKeys.

CannaKeys has 186 studies associated with Pharma THC.

Here is a small sampling of Pharma THC studies by title:


Components of the Pharma THC Research Dashboard

  • Top medical conditions associated with Pharma THC
  • Proven effects in clinical trials for Pharma THC
  • Receptors associated with Pharma THC
  • Individual study details for Pharma THC

Ready to become a subscriber? Go to our PRICING page.

Select New Cannabinoid

Filter Cannabinoid

Members can filter by the following criteria:

  • Study Type
  • Organ Systems
  • Terpenes
  • Receptors
  • Ligands
  • Study Result
  • Year of Publication

Overview - Pharma THC

Description of Pharma THC

Pharmaceutical drugs containing THC correspond to a cannabis chemotype I. They represent a class of drugs that are primarily produced and standardized from synthetic sources. Here we highlight dronabinol:

• Dronabinol is a synthetic version of THC.
• FDA approved in 1985 for the tx of HIV/AIDs-induced anorexia & chemotherapy-induced nausea.
• Off-label use include chronic pain, obstructive sleep apnea, substance abuse and withdrawal.
• Dronabinol is available as soft gelatin capsules 2.5 mg (white), 5 mg (dark brown), and 10mg (orange).
• Contraindication to dronabinol include a history of hypersensitivity reaction to sesame oil or THC derivatives.
• Most common adverse effects may include changes in cognition, dizziness, euphoria, nausea, anxiety, vomiting, or abdominal discomfort for instance.
• Dronabinol has a half-life of ~4 hours.

Other Names:

Pharmaceutical THC
Dronabinol, Marinol, Delta9-Tetrahydrocannabinol, Delta9-THC (plus various other supplier-based synonyms).

IUPAC Name: (6aR,10aR)-6,6,9-trimethyl-3-pentyl-6a,7,8,10a-tetrahydrobenzo[c]chromen-1-ol

Molecular Formula: C21H30O2

Source–PubChem

Pharma THC Properties and Effects

FDA approved for:
• Refractory chemotherapy-induced nausea and vomiting
• Anorexia/weight loss in patients with AIDS

Pharma THC Receptor Binding

Endocannabinoid System (ECS):
• CB1
• CB2

Endocannabinoidome (eCBome)
• Serotonin receptors

Disclaimers: Information on this site is provided for informational purposes only and is not meant to substitute for the advice provided by your own physician or other medical professional. You should not use the information contained herein for diagnosing a health problem or disease. If using a product, you should read carefully all product packaging. If you have or suspect that you have a medical problem, promptly contact your health care provider.

Information on this site is based on scientific studies (human, animal, or in vitro), clinical experience, or traditional usage as cited in each article. The results reported may not necessarily occur in all individuals. For many of the conditions discussed, treatment with prescription or over-the-counter medication is also available. Consult your physician, nutritionally oriented health care practitioner, and/or pharmacist for any health problem and before using any supplements or before making any changes in prescribed medications.